Combination immunotherapy: a road map

Overview of attention for article published in Journal for Immunotherapy of Cancer, February 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 23 news stories from 13 outlets.

HALIFAX, NOVA SCOTIA--(Marketwired - May 16, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and…

Company's Clinical Program Continues to Expand with Second Phase 2 Trial Announced This Year Evaluating the Combination of DPX-Su…

HALIFAX, NOVA SCOTIA -- (Marketwired) -- 05/16/17 -- Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and…

HALIFAX, NOVA SCOTIA -- (Marketwired) -- 05/16/17 -- Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 19 additional news stories.